2022
DOI: 10.3389/fneur.2022.994396
|View full text |Cite
|
Sign up to set email alerts
|

Treatment recommendations for non-HIV associated cryptococcal meningoencephalitis including management of post-infectious inflammatory response syndrome

Abstract: Cryptococcal meningoencephalitis (CM) continues to cause major morbidity and mortality in a range of patients such as those immunosuppressed from HIV and with biologic immunosuppressants, including treatments of autoimmunity, malignancies, and conditioning regimens for transplantation. It is currently the most common cause of non-viral meningitis in the United States. Infections in previously healthy patients also develop with autoantibodies to granulocyte-macrophage colony stimulating factor or with monogenet… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
9
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 99 publications
0
9
0
Order By: Relevance
“…Cryptococcal IRIS induces an aberrant inflammatory cascade that eventuates in host-mediated neuropathology ( 51 ). Experimental in vivo and in vitro inquiries posited that the pathogenesis of this affliction may originate from the hyperactivation of CD4+ T cells, engendering a cellular immune response that precipitates the proliferation of a myriad of inflammatory mediators within the central nervous system, including TNF-α, IFN-γ, and IL-6 ( 52 , 53 ). Furthermore, the established therapeutic protocol for Cryptococcus infection comprises a triad of amphotericin B, flucytosine, and fluconazole.…”
Section: Discussionmentioning
confidence: 99%
“…Cryptococcal IRIS induces an aberrant inflammatory cascade that eventuates in host-mediated neuropathology ( 51 ). Experimental in vivo and in vitro inquiries posited that the pathogenesis of this affliction may originate from the hyperactivation of CD4+ T cells, engendering a cellular immune response that precipitates the proliferation of a myriad of inflammatory mediators within the central nervous system, including TNF-α, IFN-γ, and IL-6 ( 52 , 53 ). Furthermore, the established therapeutic protocol for Cryptococcus infection comprises a triad of amphotericin B, flucytosine, and fluconazole.…”
Section: Discussionmentioning
confidence: 99%
“…Treatment focuses on controlling inflammation with corticosteroids while addressing the underlying cause by optimizing antifungal therapy. PIRS requires prompt recognition to prevent long-term neurological complications and careful management balancing anti-inflammatory measures with the need for continued infection control [ 15 ]. Therefore, when the condition of a patient being treated for CM worsens, PIRS should be considered.…”
Section: Discussionmentioning
confidence: 99%
“…Arguably the biggest question is the best treatment regimen for this patient group. Unfortunately, there is a lack of data in the non-HIV, nontransplant group, and treatment recommendations are extrapolated from patients with HIV [ 75 ]. Recently, Ssebambulidde et al did provide recommendations for non-HIV-associated cryptococcal meningoencephalitis, but the recommendations were still extrapolated mainly from patients with HIV [ 76 ].…”
Section: Discussionmentioning
confidence: 99%